Evidence map›Paper›PMID 34754203›Full record

ArticleInfection and drug resistance2021

Point Prevalence Survey of Antimicrobial Use in Four Tertiary Care Hospitals in Mexico.

Federico A Zumaya-Estrada, Alfredo Ponce-de-León-Garduño, Edgar Ortiz-Brizuela, Juan Carlos Tinoco-Favila, Patricia Cornejo-Juárez, Diana Vilar-Compte, Alejandro Sassoé-González, Pedro Jesus Saturno-Hernandez, Celia M Alpuche-Aranda

Abstract read
In one paragraph

Article in Infection and drug resistance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Presence and Persistence ofMicroorganisms · 2024
    Article
  4. Antimicrobial Resistance Patterns and Clonal Distribution ofAntibiotics (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Federico A Zumaya-EstradaCenter for Infectious Diseases Research (CISEI), National Institute of Public Health (INSP), Cuernavaca, C.P. 62100, Morelos, México.
Alfredo Ponce-de-León-GarduñoInfectology Department, National Institute of Medical Sciences and Nutrition "Salvador Zubirán", Ciudad de México, C.P. 14080, México.
Edgar Ortiz-BrizuelaInfectology Department, National Institute of Medical Sciences and Nutrition "Salvador Zubirán", Ciudad de México, C.P. 14080, México.ORCID 0000-0001-7169-8459
Juan Carlos Tinoco-FavilaInfectology Department, Hospital General 450, Secretary of Health of Durango, Durango, C.P. 34206, Durango, México.
Patricia Cornejo-JuárezInfectious Diseases Department, National Institute of Cancer (INCan), Ciudad de México, C.P. 14080, México.
Diana Vilar-CompteInfectious Diseases Department, National Institute of Cancer (INCan), Ciudad de México, C.P. 14080, México.
Alejandro Sassoé-GonzálezEpidemiological Intelligence Unit, High Specialty Regional Hospital of Ixtapaluca, Estado de México, C.P. 56530, México.
Pedro Jesus Saturno-HernandezCenter for Evaluation and Surveys Research (CIEE), National Institute of Public Health (INSP), Cuernavaca, C.P. 62100, Morelos, México.ORCID 0000-0002-4991-5805
Celia M Alpuche-ArandaCenter for Infectious Diseases Research (CISEI), National Institute of Public Health (INSP), Cuernavaca, C.P. 62100, Morelos, México.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo describe the antimicrobial use in four tertiary care hospitals in Mexico. PATIENTS AND

methodsPoint prevalence surveys (PPSs) were conducted on medical records of hospitalized patients with prescribed antimicrobials (AMs) in four tertiary care hospitals in Mexico in 2019. Prevalence estimates and descriptive statistics were used to present the collected data on antimicrobial prescribing and microbiological studies.

resultsThe prevalence of patients with prescribed AMs among the hospitals ranged from 47.1% to 91.3%. Antibiotics for systemic use (J01s) were the most prescribed (84.6%, [95% CI: 81.5-87.3]), mainly extended-spectrum J01s: third-generation cephalosporins 19.8% [95% CI: 16.8-23.1], and carbapenems 17.0% [95% CI: 14.2-20.2]. Antibiotic treatments were largely empirical, with no planned duration or review dates. The ceftriaxone use was excessive and prolonged. No formal reference guidelines for antimicrobial prescribing were available in the hospitals. Multidrug-resistant

conclusionThis study describes the extensive use of antimicrobials and broad-spectrum antibiotics for systemic use in Mexican hospitals, along with the presence of resistant pathogens to the antibiotics frequently used in the hospitals surveyed.

Indexed as

antibioticsantimicrobial useMexican hospitalsPPSs

Identifiers

PMID34754203
PMCPMC8572044

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.